Best Pharma Stocks in October 2026 Based on 5-Year CAGR: Neuland Laboratories, Wockhardt and More

The pharmaceutical sector has seen various companies demonstrate impressive growth over the past 5 years.
This article highlights the top 10 pharma stocks based on their 5-year compound annual growth rate (CAGR), offering a glimpse into their financial performance and market standing.
Top 10 Pharma Stocks Based on 5-Year CAGR in October 2026
| S.No | Name | Market Cap (in ₹ Crore) | PE Ratio | PB Ratio | Return on Equity | ROCE | 1 Year Return (%) | 5 Year CAGR (%) |
| 1 | Neuland Laboratories Limited | 27423.89 | 75.34 | 14.63 | 21.42 | 23.11 | 48.1 | 68.6 |
| 2 | Wockhardt Limited | 35654.03 | 167.39 | 6.75 | 4.29 | 6.48 | 40.26 | 39.84 |
| 3 | Marksans Pharma Limited | 15532.19 | 37.17 | 5.09 | 15.08 | 17.56 | 106.05 | 38.05 |
| 4 | Glenmark Pharmaceuticals Limited | 68905.15 | 50.6 | 6.56 | 14.07 | 16.21 | 24.68 | 36.83 |
| 5 | Strides Pharma Science Limited | 10808.17 | 19.43 | 3.43 | 19.39 | 21.66 | 43.82 | 35.1 |
| 6 | Shilpa Medicare Limited | 20648.55 | 84.86 | 7.97 | 9.82 | 12.39 | 175.19 | 30.9 |
| 7 | Laurus Labs Limited | 1,06,927.79 | 120.31 | 19.69 | 17.72 | 19.67 | 135.33 | 26.97 |
| 8 | Torrent Pharmaceuticals Limited | 1,86,152.03 | 86.05 | 10.59 | 17.19 | 9.24 | 36.45 | 25.57 |
| 9 | Caplin Point Laboratories Limited | 20857.61 | 32.53 | 5.74 | 19.68 | 22.01 | 36.5 | 25.25 |
| 10 | Granules India Limited | 23643.19 | 39.73 | 4.65 | 13.52 | 16.09 | 68.43 | 21.85 |
Note: The above data is as of September 29, 2026.
Neuland Laboratories Limited
Neuland Laboratories Limited leads with a 5-year CAGR of 68.6%. With a market cap of ₹27,423.89 crore and a close price of ₹21,375, the company has shown a 1-year return of 48.1%. The PE ratio stands at 75.34, while the return on equity is 21.42%.
Wockhardt Limited
Wockhardt Limited follows with a 5-year CAGR of 39.84%. Its market cap is ₹35,654.03 crore, and the close price is ₹2,194.2. The company has achieved a 1-year return of 40.26% and a PE ratio of 167.39.
Marksans Pharma Limited
Marksans Pharma Limited has a 5-year CAGR of 38.05%. The market cap is ₹15,532.19 crore, with a close price of ₹342.75. The 1-year return is 106.05%, and the PE ratio is 37.17.
Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited reports a 5-year CAGR of 36.83%. With a market cap of ₹68,905.15 crore and a close price of ₹2,441.5, the company has a 1-year return of 24.68% and a PE ratio of 50.6.
Strides Pharma Science Limited
Strides Pharma Science Limited has a 5-year CAGR of 35.1%. The market cap is ₹10,808.17 crore, and the close price is ₹1,172.6. The 1-year return is 43.82%, with a PE ratio of 19.43.
Shilpa Medicare Limited
Shilpa Medicare Limited shows a 5-year CAGR of 30.9%. Its market cap is ₹20,648.55 crore, and the close price is ₹1,055.75. The 1-year return is 175.19%, and the PE ratio is 84.86.
Laurus Labs Limited
Laurus Labs Limited has a 5-year CAGR of 26.97%. The market cap is ₹1,06,927.79 crore, with a close price of ₹1,979. The 1-year return is 135.33%, and the PE ratio is 120.31.
Torrent Pharmaceuticals Limited
Torrent Pharmaceuticals Limited reports a 5-year CAGR of 25.57%. With a market cap of ₹1,86,152.03 crore and a close price of ₹4,894, the company has a 1-year return of 36.45% and a PE ratio of 86.05.
Caplin Point Laboratories Limited
Caplin Point Laboratories Limited has a 5-year CAGR of 25.25%. The market cap is ₹20,857.61 crore, and the close price is ₹2,744. The 1-year return is 36.5%, with a PE ratio of 32.53.
Granules India Limited
Granules India Limited rounds off the list with a 5-year CAGR of 21.85%. The market cap is ₹23,643.19 crore, and the close price is ₹866.75. The 1-year return is 68.43%, and the PE ratio is 39.73.
Read More: Lemon Tree Hotels Share Price in Focus; Opens New 71-Room Resort in Nashik!
Conclusion
The top 10 pharma stocks based on 5-year CAGR include Neuland Laboratories at 68.6%, Wockhardt at 39.84%, and Marksans Pharma at 38.05%. These companies have shown varied market caps, PE ratios, and 1-year returns.
Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Turn insights into action - Open Free Demat Account with Angel One and start investing instantly.
Published on: Sep 30, 2026, 2:47 PM IST

Team Angel One
- Indian IT Stocks in Focus; Top Five Firms Add 16,055 Employees in H1FY27 but Demand Recovery Remains Uncertain
- BPCL Share Price in Focus as Q2FY27 Net Profit Declines 22.5%
- Paradeep Phosphates Share Price in Focus; Signs MoU for ₹4,750 Crore Investment in Odisha
- Aditya Birla Real Estate Share Price in Focus as Birla Estates Announces ₹1,650 Crore Pune Project
- Bajaj Finserv Share Price in Focus; Subsidiary Names Deepak Reddy as CEO Designate




